Biblio

Export 5 results:
Author Keyword Title [ Type(Asc)] Year
Filters: Author is Aisen, Paul S  [Clear All Filters]
Journal Article
C. R. Jack, Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., Lesnick, T. G., Pankratz, V. S., Donohue, M. C., and Trojanowski, J. Q., Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers., Lancet Neurol, vol. 12, no. 2, pp. 207-16, 2013.
R. A. Sperling, Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., and Phelps, C. H., Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease., Alzheimers Dement, vol. 7, no. 3, pp. 280-92, 2011.
R. S. Doody, Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., Siemers, E., Liu-Seifert, H., and Mohs, R., Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
C. R. Jack, Vemuri, P., Wiste, H. J., Weigand, S. D., Aisen, P. S., Trojanowski, J. Q., Shaw, L. M., Bernstein, M. A., Petersen, R. C., Weiner, M. W., and Knopman, D. S., Evidence for ordering of Alzheimer disease biomarkers., Arch Neurol, vol. 68, no. 12, pp. 1526-35, 2011.
S. Sokolow, Li, X., Chen, L., Taylor, K. D., Rotter, J. I., Rissman, R. A., Aisen, P. S., and Apostolova, L. G., Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment., J Alzheimers Dis, vol. 56, no. 1, pp. 229-237, 2017.